Abstract

Cord blood collection has emerged as a promising approach for autologous cell therapy, offering potential benefits for extremely preterm infants who are at high risk for various complications. This review explores the challenges and opportunities associated with cord blood collection for autologous use in these vulnerable patients. Key challenges include the limited volume of cord blood often available from extremely preterm infants, which can impact the quantity and quality of cells collected. Additionally, the medical and logistical complexities of collecting and processing cord blood in the context of extreme prematurity must be carefully managed. Despite these challenges, there are significant opportunities, such as advancements in collection techniques and storage methods, that may enhance the feasibility and utility of cord blood for autologous therapies. This review aims to provide a comprehensive overview of current practices, potential solutions to existing challenges, and future directions in the field of cord blood collection for extremely preterm infants.